Inflammation in Atherosclerosis

Peter Libby

Abstract—Experimental work has elucidated molecular and cellular pathways of inflammation that promote atherosclerosis. Unraveling the roles of cytokines as inflammatory messengers provided a mechanism whereby risk factors for atherosclerosis can alter arterial biology, and produce a systemic milieu that favors atherothrombotic events. The discovery of the immune basis of allograft atherosclerosis demonstrated that inflammation per se can drive arterial hyperplasia, even in the absence of traditional risk factors. Inflammation regulates aspects of plaque biology that trigger the thrombotic complications of atherosclerosis. Translation of these discoveries to humans has enabled both novel mechanistic insights and practical clinical advances. (Arterioscler Thromb Vasc Biol. 2012;32:2045-2051.)

Inflammation: An Enduring Flame

For much of the last century, most people considered atherosclerosis to be a cholesterol storage disease characterized by the collection of cholesterol and thrombotic debris in the artery wall. The modern era of the cell biology of atherosclerosis in the 1960s and 1970s focused on the proliferation of smooth muscle cells as the nidus for atherosclerotic plaques. Over the last quarter century, the concept that inflammation plays a primordial role in atherogenesis has gained ascendency. Yet, as with many innovations in science and medicine, the roots of this seemingly modern concept stretch far back in time.

Innate Immunity in Atherosclerosis

Since Virchow’s day, pathologists have recognized lipid–ladden foam cells as a hallmark of atheromata. The advent of rigorous cell identification, enabled by the development of monoclonal antibodies, led to the confirmation that most foam cells arise from mononuclear phagocytes, although smooth muscle cells and endothelial cells can also become engorged with lipids. Still, most viewed macrophages as the graveyard of lipids in the plaque rather than as active participants in atherogenesis. Death of foam cells would lead to formation of the necrotic core, conceived as a depot of cellular debris and lipids. Indeed, some early schemes of the cell biology of atherosclerosis depicted atherogenesis as a bland process, without the participation of inflammatory cells. The role of the mononuclear phagocyte as an effector emerged with the characterization of macrophage-derived mediators, such as cytokines. The concept of dynamic interplay between mononuclear phagocytes and vascular cells during atherogenesis, once overlooked or doubted, has now become commonplace (Figure 1).

Inflammatory Cells Function in Atherogenesis

The discovery of adhesion molecules, expressed by endothelial cells, provided important insight into the initiation of atherosclerotic lesions. For example, vascular cell adhesion molecule-1, expressed by cytokine–stimulated endothelial cells, binds just those types of inflammatory cells that aggregate in the early atherosclerotic plaque: monocytes and T lymphocytes. The characterization of leukocyte adhesion molecules provided a mechanism for the sticking of the mononuclear cells to intact

© 2012 American Heart Association, Inc.
endothelium in hypercholesterolemic rabbits observed by Poole and Florey\(^\text{11}\) in 1958. Once adherent to the endothelial surface attributable to the expression of inducible adhesion molecules, the mononuclear cells receive chemotacttractant signals that beckon them to enter the intima. Chemotacttractants, such as monocyte chemoattractant protein-1, contribute importantly to this process.\(^\text{12}\) A trio of chemokines induced by interferon-\(\gamma\) (IFN-\(\gamma\)) also selectively recruit T lymphocytes to the nascent atherosclerotic plaque.\(^\text{13}\)

Once resident in the arterial intima, monocytes mature into macrophages. In the plaque, these mononuclear phagocytes express scavenger receptors necessary for uptake of modified lipoproteins and, hence, foam cell formation. In a quest to identify the mechanisms that mediate macrophage maturation, we and others localized macrophage colony-stimulating factor (M-CSF) in plaques.\(^\text{14,15}\) In vitro studies showed that M-CSF could induce scavenger receptors and promote the proliferation of monocytes in early atherosclerotic lesions.\(^\text{14}\) Formation of the necrotic core may also reflect highly regulated functions of mononuclear phagocytes. We wrote in 1992:

“The death of lipid laden macrophages may not be a random event or simply caused by bursting like an over-inflated balloon due to lipid overload. Rather, this process may resemble apoptosis, a form of programmed cell death. The necrobiosis in the fatty core of lesions may be due in part to gradients of concentration of factors such as M-CSF required for survival of human monocytes. Overexpression of M-CSF may occur in the ‘shoulder’ or leading edge of the evolving lesion, a region characterized by ongoing cellular activation. On the other hand, relative depletion of M-CSF in the central core of a plaque could favor necrobiosis.”\(^\text{16}\)

Macrophages also contribute to the thrombotic complications of atherosclerosis in pivotal ways. These phagocytes furnish the bulk of the enzymes that catabolize collagen, a key constituent of the fibrous cap of the plaque. We hypothesized in the early 1990s that overproduction of the interstitial collag enase members of the matrix metalloproteinase (MMP) family jeopardizes the biomechanical stability of the protective fibrous cap of the plaque, predisposing to plaque rupture.\(^\text{17}\) We described overexpression of interstitial collagenases (MMP-1, MMP-8, and MMP-13) in human atheromata and colocalized macrophages bearing these proteinases with degradation products of interstitial collagen within plaques.\(^\text{18}\) Our subsequent experiments elucidated the proinflammatory cytokines that can promote the expression of MMP interstitial collagenases by mononuclear phagocytes, setting the stage for plaque disruption and thrombosis. Our group subsequently substantiated the role of MMP collagenases in plaque collagen content using genetic or pharmacological gain-of-function or loss-of-function experiments in mice.\(^\text{19–22}\)

Macrophages and smooth muscle cells within atherosclerotic plaques also overexpress the potent procoagulant tissue factor. We identified the inflammatory mediator CD40 ligand (CD154) as a disease-relevant activator of tissue factor expression by human macrophages.\(^\text{23}\) Thus, inflammation regulates both the thrombogenicity of the plaque and the integrity of the protective fibrous cap of the plaque. These findings provided firm evidence linking inflammation to the thrombotic complications of atherosclerosis. This thread of discoveries demonstrated that inflammatory mediators participate in all phases of atherogenesis, from lesion initiation through progression and ultimately to the clinical complications of this disease.

**Vessel Wall Cell–Derived Cytokines Can Provide Kindling for the Innate Immune Response in Atherosclerosis**

Our discovery that vascular wall cells themselves can produce cytokines, protein mediators of inflammation and

---

**Figure 1.** This drawing (made with the original MacPaint application by the author) presents an early (1989) depiction of the cross talk between inflammatory cells and intrinsic factor wall cells mediated by cytokines. Work from around the world has now verified the principle points postulated in this primitive picture, a precursor of countless subsequent schemata. The T lymphocyte depicted at the apex of the diagram responds to antigenic stimulation by elaborating cytokines, such as interferon-\(\gamma\) (IFN-\(\gamma\)), lymphotxin (LT), and tumor necrosis factor-\(\alpha\) (TNF–\(\alpha\)). This sequence represents the adaptive immune response. These cytokines impinge upon the macrophage/monocyte depicted in the middle of the diagram that can elaborate mediators of innate immunity, such as interleukin (IL)-1 and IL-6, in response, as well as a material then denoted platelet–derived growth factor cross-reactive material (PDGFc), and transforming growth factor-\(\alpha\) (TGF–\(\alpha\)). Monocytes/macrophages thus comprise a major cell type involved in innate immunity. These cytokines produced by mononuclear phagocytes in turn mediate paracrine signaling to endothelial cells (ECs, lower left) or vascular smooth muscle cells (SMCs, lower right).\(^\text{47}\) HLA indicates human leukocyte antigen.
immunity, provided an important insight into the initiation of atherosclerosis. According to the original concept, cytokines functioned to signal between leukocytes, and hence the name interleukin (IL). Our work in the 1990s demonstrated that human endothelial cells and smooth muscle cells not only responded to cytokines but also could produce these proinflammatory mediators. Products of oxidized lipoproteins and angiotensin II, substances closely related to classic risk factors for atherosclerosis such as hyperlipidemia and hypertension, could provoke vascular wall cells to produce cytokines. Thus, an early stimulus for the recruitment of professional inflammatory cells to the lesion might arise from the production of cytokines by local vascular wall cells that elicit adhesion molecule and chemoattractant expression.

Before lesions take root, intrinsic vascular wall cells may sustain the initial assault from atherosclerotic risk factors and respond by elaborating proinflammatory mediators that then recruit and activate professional inflammatory cells that amplify and sustain the inflammation in the nascent lesion. These findings stimulated the view of atherosclerosis as a dynamic and multilateral interchange between vascular wall cells and leukocytes, challenging the earlier notion of vascular cells as mere bystanders in arterial inflammation and of foam cells as passive receptacles for lipid debris.

**Inflammation and Death of Cells in Atheromata**

As atherosclerotic lesions evolve, macrophage foam cells and smooth muscle cells can undergo apoptosis. As noted above, macrophage death contributes to lipid core formation. Smooth muscle cell apoptosis, a process we proposed as potentiated by inflammatory mediators, also likely contributes to lesion complication. We advanced in 1995 the explicit hypothesis that smooth muscle cell death explains why regions of plaques that rupture and trigger thrombosis contain few of these cells. Smooth muscle cells produce most of the arterial interstitial collagen that lends strength to the fibrous cap. Thus, a paucity of smooth muscle cells attributable to apoptosis could also contribute to a lack of collagen in inflamed plaques, a property associated with their propensity to rupture and provoke thrombosis. We also presented data in this early description of apoptosis in atheromata that pointed to what we termed prolonged persistence of cells undergoing apoptosis in these lesions. We stated: “Some apoptotic cells may not disappear from the atherosclerotic lesions but accumulate in the fibrotic lesions in a ‘mummified’ state.” The elegant subsequent studies of Ira Tabas have elaborated this concept of impaired clearance, or efferocytosis, of apoptotic cells in plaques.

**Heterogeneity of Mononuclear Phagocytes in Atherosclerosis**

Recent work has shed new light on the long appreciated heterogeneity of monocyte/macrophage functions observed in atherosclerotic plaques. Our group provided early evidence in 1992 of heterogeneity of macrophage functions based on gene expression. The use of more recently recognized cell surface markers has revealed a striking dichotomy in monocytes in atherosclerosis. Hypercholesterolemic mice have high levels of monocytes that exhibit particularly proinflammatory functions, delineated by high expression of the surface marker Ly6C, in the peripheral blood and spleen. In severely hypercholesterolemic mice, extramedullary leukopoiesis in the spleen yields enhanced production of this proinflammatory subset of monocytes. These cells exit the spleen and can accumulate in atheromata, furnishing a substantial minority of the mononuclear phagocytes in experimental lesions.

The proinflammatory subset of monocytes may preferentially give rise to macrophages that exhibit a proinflammatory program known as classic activation. Some refer to macrophages exhibiting a primary proinflammatory program as M1 macrophages. The simplistic dichotomization of macrophages into categories based on certain markers may have heuristic value, but applies more to mice than to humans, and glosses over overlapping patterns of activation that characterize complex chronic inflammatory processes in humans, such as atherosclerosis.

Recent advances in understanding the heterogeneity of mononuclear phagocytes in atherosclerosis offer new mechanistic insight into this disease and provide new avenues for manipulation of the immune response during atherogenesis. The extent to which these observations in mice with exaggerated levels of hypercholesterolemia apply to humans remains under investigation.

**Innate Immunity in Atherogenesis: Beyond Phagocytes**

Macrophages account for the vast majority of leukocytes found in atheromata. Other effector cells of innate immunity, although less numerous, may also contribute to the pathogenesis of atherosclerosis. Mast cells, long noted in the adventitia and postulated to contribute to vascular diseases, have recently emerged as participants in experimental atherogenesis. The morphological findings of the 1950s have given way to pharmacological and genetic interventions that disclose a proatherogenic role for the mast cells in mouse atherosclerosis. Our group found that a genetically determined lack of mast cells ameliorates experimental atherosclerosis in mice. Adoptive transfer experiments have implicated mast cell–derived IL-6 and IFN-γ as proinflammatory mediators that contribute to lesion evolution. Eosinophils, and notably IgE activation, also can aggravate experimental atherosclerosis.

**Adaptive Immunity in Atherosclerosis**

Macrophages comprise the vast majority of inflammatory cells in human and experimental atherosclerotic plaques. The cells of adaptive immunity, namely T lymphocytes and B lymphocytes, also exist in atherosclerotic lesions, albeit in markedly lower numbers. Despite their minority status, lymphocytes, particularly T lymphocytes, appear to function decisively in the regulation of inflammation during atherogenesis. Armies have more foot soldiers than generals, and orchestras contain many instrumentalists but only 1 conductor; likewise, the less numerous T lymphocytes may regulate the innate inflammatory response in atherosclerosis, mediated by macrophages within plaques. A previous article in this series by Hansson and Jonsson has covered in depth the discovery of cellular immunity in the atherosclerotic plaque, only briefly summarized here. Immunolocalization first documented the presence of T lymphocytes in human...
Atheromata. The expression of class II histocompatibility antigens by neighboring cells provided evidence for the functional significance of these T cells. T lymphocytes produce IFN-\(\gamma\), the inducer of class II major histocompatibility complex antigens in smooth muscle cells and macrophages. Adoptive transfer experiments proved a pathogenic role for CD4+ T lymphocytes in mouse atherosclerosis. Further study disclosed an early predominance of IFN-\(\gamma\)–producing Th1 CD4+ cells in mouse atheromata. Subsequent studies have identified potential endogenous antigens, including low-density lipoprotein (LDL) and heat shock protein-60, which may stimulate adaptive immunity in atherosclerotic plaques. Like mononuclear phagocytes, T lymphocytes exhibit functional diversity. Although Th1 CD4+ lymphocytes appear to accelerate atherogenesis, regulatory T cells, through the secretion of transforming growth factor-\(\beta\) and in some cases IL-10, appear to limit atherosclerosis. Thus, the balance between T-cell subsets may influence the formation and character of lesions.

B cells also populate plaques. Humoral immunity, however, appears to mitigate atherogenesis. Thus, B1 cells that give rise to natural antibody may protect against atherosclerosis. Splenectomy, an intervention that reduces B-lymphocyte levels, can enhance atheroma formation in mice. Vaccination with putative antigens, such as modified LDL, appears to protect against atherosclerosis. In contrast, B2 lymphocytes may aggravate atherogenesis. Indeed, depletion of B cells with anti-CD20 antibody treatment limits lesion size in mice in an IL-17–dependent manner. Thus, the net influence of B-cell functions in atherosclerosis remains unsettled.

**Allograft Vasculopathy: A Special Case of Immune-Mediated Atherosclerosis**

Recipients of solid organ allografts develop a special type of atherosclerosis known by many names, including allograft arteriopathy. This disease can develop rapidly, within a few months or a few years, even in the absence of the traditional risk factors of atherosclerosis. Involvement of the donor arteries, with sparing of the host arteries, indicates that this accelerated arteriopathy does not result from a systemic change attributable to the transplanted state or from the medications used to control acute rejection.

We postulated in 1989 that an immune response directed against foreign class II histocompatibility antigens expressed by donor cells stimulated a chronic cytokine-mediated immune response that led to this concentric fibroproliferative form of atherosclerosis (Figure 1). Our group demonstrated the expression of class II histocompatibility antigens on endothelial cells in the coronary arteries of cardiac allografts. Further observations localized T lymphocytes in a subendothelial position in the intima, in a ring-like array (Figure 2). We predicted a key role for IFN-\(\gamma\) derived from activated T cells in the induction of class II antigens and the initiation of the pathogenic cascade of allograft arteriopathy. Our group further postulated that the chronic immune response in this disease, akin to a delayed–type hypersensitivity reaction, differed from CD8 T cell–mediated cytolysis, the hallmark of parenchymal rejection. In 1997, our studies in genetically modified mice provided direct experimental support for these conjectures: IFN-\(\gamma\) deficiency prevented coronary atherosclerosis but not myocardial rejection in cardiac allografts. Although other immune and nonimmune mechanisms contribute to the pathogenesis of allograft arteriopathy, a combination of experimental and human observations establishes adaptive immunity as a key element in the development of this disease. This example illustrates indubitably that inflammatory mechanisms can produce atherosclerosis in the absence of classic risk factors, such as hyperlipidemia.

**Implications of Inflammation in Atherosclerosis for Translation to Human Disease**

The recognition of the operation of inflammation in atherogenesis spawned the application of biomarkers of inflammation to extend the experiments on animals and cultured cells and observations on human specimens...
and intact subjects. Biomarkers of inflammation, such as C-reactive protein (CRP), rise in individuals with acute myocardial infarction.\textsuperscript{50,51} Such observations, made many years ago, likely reflect the response to tissue injury. Evidence accumulated over the last 15 years demonstrates that subtle increases in biomarkers of inflammation (such as CRP) can augur future cardiovascular events in apparently healthy people.\textsuperscript{52} The fluctuations of CRP that predict enhanced cardiovascular risk occur within the range of this biomarker, far below levels encountered in individuals with acute illnesses. The development of a high-sensitivity assay (denoted hsCRP) thus permitted accurate measurement of this biomarker as a tool to enhance risk stratification. In contrast to many other novel biomarkers, hsCRP adds to the traditional risk factors for atherosclerosis encompassed in the Framingham algorithm. The increase in the relative risk estimate of those with higher quantiles of hsCRP, adjusted for traditional risk factors, is modest: \textasciitilde1.5 to 1.7. Yet after age and sex, the addition of traditional risk factors, such as total cholesterol and systolic blood pressure, yield about the same increment in risk prediction.\textsuperscript{53} Recently developed tools for gauging the clinical use of novel biomarkers, such as the net reclassification index, show that hsCRP can correctly reclassify individuals, particularly in the group categorized as having intermediate risk according to traditional criteria. This intermediate risk group accounts for much of the burden of cardiovascular events. Some guidelines and recommendations from professional societies now incorporate hsCRP into risk-predicting algorithms. The Reynolds risk score, in particular, adds hsCRP and family history of premature coronary artery disease to traditional risk factors in a clinically useful manner.\textsuperscript{54}

The successful application of biomarkers of inflammation to sharpen cardiovascular risk assessment, and its independence from traditional risk factors such as hypercholesterolemia, suggested that biomarkers of inflammation could identify individuals who might benefit from intervention, despite relatively low estimates of cardiovascular risk based on traditional risk factors. Statin drugs, for example, effectively lower LDL and reduce cardiovascular risk in broad categories of individuals and also reduce inflammation as gauged by lowering of CRP. Within an individual, the statin-induced drop in LDL correlates very poorly with the fall in CRP. This observation, replicated in numerous large clinical trials, indicates that LDL and inflammation vary independently. Retrospective analysis of 1 large trial that treated individuals without known cardiovascular disease with a statin showed that the reduction of events in those with below–median LDL levels, but above–median CRP levels, resembled that achieved by treatment of those with LDL levels above the median.\textsuperscript{55}

These considerations inspired Dr Paul M Ridker to design and conduct a large–scale clinical trial known as JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). It enrolled more than 17 000 individuals without known cardiovascular disease with hsCRP \textasciitilde2 mg/L and LDL cholesterol levels <130 mg/dL. The study results showed a reduction \textasciitilde40\% in first-ever cardiovascular events due to statin treatment.\textsuperscript{56} The statin-treated group also had decreased all-cause mortality, even though the study was not powered for a mortality effect. Prespecified analyses of JUPITER indicated that the clinical benefit derived both from LDL lowering and an anti-inflammatory effect reflected by reduction in CRP.\textsuperscript{57} These results in an apparently healthy population agreed with previous findings in the clinical trials of patients who survived an acute coronary syndrome.

JUPITER was not designed to prove, nor could it prove, that a direct anti-inflammatory therapy reduces atherosclerotic events. Testing this hypothesis will require additional clinical trials, and several such investigations are underway or in the planning stage. The Canakinumab Anti-Thrombosis Outcome Study (CANTOS) will test whether administration of an antibody that neutralizes the proinflammatory cytokine IL-1β can reduce cardiovascular events in survivors of myocardial infarction who have hsCRP levels persistently \textasciitilde2 mg/dL, despite standard-of-care therapy including treatment with high-dose statins.\textsuperscript{58} The Cardiovascular Inflammation Reduction Trial (CIRT) will test whether treatment of a similar population with weekly low-dose methotrexate, a regimen used successfully in the management of rheumatoid arthritis, can reduce recurrent cardiovascular events.\textsuperscript{59} In the realm of adaptive immunity, studies are exploring the feasibility of vaccination with oxidized LDL–derived antigens to elicit a humoral immune response that could protect against atherosclerotic events.\textsuperscript{60} Such studies should permit testing of the proposition that interfering with innate or adaptive immunity, and breaking the cycle of inflammation during atherosclerosis, can improve outcomes. Given the complexities and redundant mediators and signaling pathways involved in vascular inflammation, clinical validation of the inflammation hypothesis of atherogenesis may require testing a number of targets to find the sweet spot of an intervention that mitigates the disease without undue impairment of host defenses.

Conclusions
The concept of inflammation contributing to atherosclerosis, rooted in keen observations in the 19th century, has undergone a research renaissance in recent decades. New tools of biological and clinical research have established a modulatory role for inflammation and immunity in experimental atherosclerosis. The validation of these concepts in humans and the translation to clinical practice are works in progress. The new understanding of the participation of inflammation in atherosclerosis, and its complications, in no way challenges the importance of traditional risk factors, such as high LDL levels, as causal risk factors for this disease (Figure 3). Indeed, inflammation provides a pathway that mechanistically links alterations in traditional risk factors and modifications in the biology of the artery wall that give rise to atherosclerosis and its complications. The coming years should prove fruitful in completing the canvas of the role of inflammation in atherosclerosis, and in translating these concepts to improve human health.
The relationship between traditional risk factors for atherosclerosis and inflammation. The concept of inflammation in atherosclerosis in no way diminishes the importance of the traditional risk factors for atherosclerosis depicted at the top of this diagram, including low-density lipoprotein (LDL) and angiotensin II (Ang II). Rather, the concept of inflammatory signaling and the participation of proinflammatory cytokines provides a mechanistic link between traditional risk factors and altered biological responses of the artery wall that drive atherosclerosis and its complications.

Acknowledgments

The author thanks the many trainees who have participated in this work through the decades, some of whose many contributions are cited in the References. I also thank the long-term professional colleagues who have contributed to the concepts of inflammation and immunity in vascular disease. Dr Jordan S. Pober contributed decisively to the early work on the pathogenesis of alloagraft arteriopathy. Dr Göran K. Hansson participated pivotal in the evolution of these concepts over 3 decades in conversations, collaborative experiments, shared trainees, and joint writings. I thank him for his critical review of this manuscript. Dr Paul M Ridker, my long-term colleague, spearheaded the clinical translation of inflammation biology to patient populations and clinical trials. I thank Sara Karwacki for expert editorial assistance and David Lynn for outstanding technical transcription.

Sources of Funding

Our work on inflammation and immunity in atherosclerosis has received support from the US National Heart, Lung, and Blood Institute, the American Heart Association, the Donald W. Reynolds Foundation, and the Fondation Leducq.

Disclosures

None.

References


Libby Inflammation in Atherosclerosis 2051
Inflammation in Atherosclerosis
Peter Libby

doi: 10.1161/ATVBAHA.108.179705
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/32/9/2045

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/